Form 4: Amicus Therapeutics CEO Campbell Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley L. Campbell, exercised stock options and sold shares on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On October 1, 2024, Bradley L. Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
- Simultaneously, Campbell sold 7,500 shares of common stock at a weighted average price of $10.599 per share, with prices ranging from $10.49 to $10.67.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.
- Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and 15,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There's no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 2023-08-23 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-01-02 | Expiration date of stock options |
| 2024-10-01 | Date of stock option exercise and share sale |
| 2024-10-04 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.